Urology San Antonio

1. Pfizer Inc. $3,337,816 42 payments
2. AstraZeneca Pharmaceuticals LP $711,967 1 payment
3. Blue Earth Diagnostics Limited $600,262 25 payments
4. Novartis Pharmaceuticals Corporation $379,173 8 payments
5. Provepharm Inc. $261,023 3 payments
6. Epizyme, Inc., $125,159 24 payments
7. E.R. Squibb & Sons, L.L.C. $114,879 5 payments
8. Ortho-Clinical Diagnostics, Inc. $30,834 2 payments
9. GlaxoSmithKline, LLC. $21,798 10 payments
10. AstraZeneca UK Limited $18,349 1 payment

1. Talapro3 A Phase 3 Randomized Doubleblind Study of Talazoparib With Enzalutamide Versus Placebo With Enzalutamide in Men With DDR Gene Mutated Metastatic Castrationsensitive Prostate Cancer $3,337,187 41 payments
2. A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 $711,967 1 payment
3. A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Men With Suspected Prostate Cancer Recurrence Based on Elevated PSA Following Prior Therapy. $342,859 5 payments
4. A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Patients With Metastatic Prostate Cancer $243,234 2 payments
5. PVP-22IC04 and PVP-22IC05 $213,884 1 payment
6. CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer $123,169 22 payments
7. A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer $114,879 5 payments
8. Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy $113,850 4 payments
9. A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) $108,353 3 payments
10. A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) Ligand in Men With Newly Diagnosed Prostate Cancer $66,011 4 payments

1. Patient care $4,808 1 payment
2. Overhead $4,808 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.